var data={"title":"Letrozole: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Letrozole: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6442?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=letrozole-drug-information\" class=\"drug drug_general\">see &quot;Letrozole: Drug information&quot;</a> and <a href=\"topic.htm?path=letrozole-patient-drug-information\" class=\"drug drug_patient\">see &quot;Letrozole: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187285\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Femara</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187286\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>ACH-Letrozole;</li>\n      <li>Apo-Letrozole;</li>\n      <li>Auro-Letrozole;</li>\n      <li>Bio-Letrozole;</li>\n      <li>Femara;</li>\n      <li>JAMP-Letrozole;</li>\n      <li>Mar-Letrozole;</li>\n      <li>MED-Letrozole;</li>\n      <li>Nat-Letrozole;</li>\n      <li>PMS-Letrozole;</li>\n      <li>RAN-Letrozole;</li>\n      <li>Riva-Letrozole;</li>\n      <li>Sandoz-Letrozole;</li>\n      <li>Teva-Letrozole;</li>\n      <li>Van-Letrozole;</li>\n      <li>Zinda-Letrozole</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1021526\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Aromatase Inhibitor</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1021558\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=letrozole-drug-information\" class=\"drug drug_general\">see &quot;Letrozole: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Delayed puberty and growth [CDGP (constitutional delay of growth and puberty)] (males):</b> Very limited data available: Adolescents &ge;14 years: Oral:  2.5 mg once daily in combination with testosterone therapy; dosing from a double-blind placebo-controlled trial of 33 adolescent males (treatment group: n=11); during the 12 months of therapy, bone maturation was delayed, predicted adult height values were significantly increased and markers of puberty progressed (Palmert; 2012; Wickman, 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>McCune-Albright syndrome; precocious puberty (females):</b> Very limited data available: Children &gt;2-10 years at time of treatment initiation: Oral: Initial: 0.5 mg/m<sup>2</sup>/day divided every 12 hours for days 1-7, then 1 mg/m<sup>2</sup>/day divided every 12 hours on days 8-14, then 1.5 mg/m<sup>2</sup>/day divided every 12 hours beginning on day 15; if needed, may further increase to 2 mg/m<sup>2</sup>/day if markers of precocious puberty including serum estradiol levels progress. Dosing based on a pilot study of nine girls (3-8 years at time of therapy initiation) which showed long-term therapy (up to 36 months) decreased rates of growth and bone maturation; although ovarian volume decreased during the first 6 months of treatment, the mean ovarian volume increased over 1-2 years of therapy with cyst redevelopment in some patients. During the pilot study, dosing was divided twice daily to alleviate GI discomfort; however, pharmacokinetic analysis showed once daily dosing would be appropriate for young children if tolerated (Feuillan, 2007).  In a case series (n=3, age range at treatment: 3-7 years), a fixed dose of 2.5 mg once daily was used for 5-19 months duration (Bercaw-Pratt, 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Short-stature; idiopathic (males):</b> Limited data available: Children and Adolescents 9-16 years: Oral: 2.5 mg once daily; dosing based experience in a double-blind, placebo-controlled trial of 30 males (treatment group: n=16; age range: 9-14 years) and a retrospective observation (n=24; age range: 9-16 years); the duration of letrozole therapy was  up to 2 years (range: 4-24 months); bone maturation delay with increases in predicted adult height values were observed with treatment (Hero, 2005; Karmazin, 2005; Shulman, 2008)  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: Females: Postmenopausal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Breast cancer, advanced (first- or second-line treatment):</b> Oral: 2.5 mg once daily; continue until tumor progression</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Breast cancer, early (adjuvant treatment):</b> Oral: 2.5 mg once daily; optimal duration unknown, duration in clinical trial is 5 years; discontinue at relapse</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Breast cancer, early (extended adjuvant treatment):</b> Oral: 2.5 mg once daily; optimal duration unknown, duration in clinical trials is 5 years (after 5 years of tamoxifen); discontinue at relapse. In clinical trials, letrozole was initiated within 3 months of discontinuing tamoxifen (Goss, 2003; Jin, 2012).  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults: CrCl &ge;10 mL/minute: No dosage adjustment is required. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment (Child-Pugh class A or B): No adjustment recommended </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment (Child-Pugh class C) or cirrhosis: 2.5 mg every other day </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187263\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Femara: 2.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2.5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187248\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24037031\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">May administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104527\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187281\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at room temperature of 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1021527\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Adjuvant treatment of hormone receptor positive early breast cancer, extended adjuvant treatment of early breast cancer after 5 years of tamoxifen, first-line treatment of hormone receptor positive or hormone receptor unknown, locally advanced or metastatic breast cancer; treatment of advanced breast cancer with disease progression following antiestrogen therapy (All indications: FDA approved in postmenopausal women); has also been used in treatment of precocious puberty associated with McCune-Albright Syndrome (MAS) in girls; constitutional delay of growth and puberty  (not due to growth hormone deficiency) and idiopathic short stature in boys</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187326\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Femara may be confused with Famvir, femhrt, Provera</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Letrozole may be confused with anastrozole</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Letaris, a formerly marketed Dutch brand name product for letrozole, may be confused with Letairis, a US brand name for ambrisentan.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187324\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Angina pectoris, cerebrovascular accident (including hemorrhagic stroke, thrombotic stroke), chest pain, chest wall pain, edema, hypertension, myocardial infarction, peripheral edema, thromboembolism (including portal vein thrombosis, pulmonary embolism, thrombophlebitis, venous thrombosis), transient ischemic attacks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, depression, dizziness, drowsiness, fatigue, headache, insomnia, pain, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, diaphoresis, night sweats, pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hot flash, hypercalcemia, hypercholesterolemia, weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dyspepsia, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Mastalgia, urinary tract infection, vaginal dryness, vaginal hemorrhage, vaginal irritation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Metastases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection, influenza, viral infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, arthritis, back pain, bone fracture, decreased bone mineral density, limb pain, myalgia, ostealgia, osteoporosis, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Cataract</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Renal disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, dyspnea, pleural effusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis, angioedema, arterial thrombosis, cardiac failure, carpal tunnel syndrome, endometrial carcinoma, endometrial hyperplasia, erythema multiforme, hepatitis, leukopenia, memory impairment, stomatitis, tachycardia, tenosynovitis (trigger finger), thrombocytopenia, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187268\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to letrozole or any component of the formulation; pregnancy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Hypersensitivity to other aromatase inhibitors; use in patients &lt;18 years of age; premenopausal endocrine status; breastfeeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187252\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause dizziness, fatigue, and somnolence; patients should be cautioned before performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Decreased bone mineral density: May cause decreases in bone mineral density (BMD). In one study, a decrease in hip BMD by 3.8% from baseline in letrozole-treated patients vs 2% in placebo at 2 years was demonstrated, however, while lumbar spine BMD was decreased, the difference was not statistically significant. Results of a safety study did demonstrate a decrease in lumbar spine BMD with letrozole (compared to tamoxifen). Osteoporosis and bone fractures have occurred at higher rates when compared to tamoxifen or to placebo. Monitor BMD.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased cholesterol: May increase total serum cholesterol. In patients treated with adjuvant therapy and cholesterol levels within normal limits, an increase of &ge;1.5 x ULN in total cholesterol (non-fasting) has been demonstrated in 8.2% of letrozole-treated patients (25% requiring lipid-lowering medications) vs 3.2% of tamoxifen-treated patients (16% requiring medications). Monitor cholesterol panel; may require antihyperlipidemics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dose adjustment recommended in patients with cirrhosis or severe hepatic dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26021958\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">In males treated for idiopathic short stature, trabecular bone and vertebral-body deformities were observed; consider prior to therapy initiation, and monitor patients closely (Palmert, 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187313\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2A6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2A6 (strong)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187257\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=94329&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Artesunate: CYP2A6 Inhibitors may decrease serum concentrations of the active metabolite(s) of Artesunate. CYP2A6 Inhibitors may increase the serum concentration of Artesunate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2A6 Substrates (High risk with Inhibitors): CYP2A6 Inhibitors (Strong) may decrease the metabolism of CYP2A6 Substrates (High risk with Inhibitors). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Aromatase Inhibitors may increase the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamoxifen: May decrease the serum concentration of Letrozole.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tegafur: CYP2A6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tegafur. Specifically, CYP2A6 inhibitors may inhibit the conversion of tegafur into its active metabolite, 5-fluorouracil. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187271\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Use is contraindicated in women with an established pregnancy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Breast cancer: Letrozole is approved for the treatment of breast cancer in postmenopausal women. Based on the mechanism of action and data from animal reproduction studies, letrozole may cause fetal harm if used during pregnancy. A pregnancy test is recommended prior to therapy in women of reproductive potential and effective contraception should be used during therapy and for at least 3 weeks following the last dose.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Infertility associated with polycystic ovarian syndrome (PCOS): Letrozole is used off-label to induce ovulation in infertile anovulatory women with PCOS (Balen 2016; Franik 2014; Legro 2013; Legro 2014; Misso 2012). Baseline testing is done prior to letrozole therapy to rule out unexpected ovulation which prevents exposure in early pregnancy (Legro 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1021564\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor periodically during therapy: Complete blood counts, thyroid function tests; serum electrolytes, cholesterol, transaminases, and creatinine; blood pressure; bone density</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Delayed puberty and short stature: In the pediatric clinical trials (study durations: 1-2 years) the following were monitored (at baseline, and then typically 2 months, 5 months, 12 months, and 18 months): Growth indices (height, adult height predictions, bone age, lumbar and femoral bone mineral density), Tanner stage and serum concentration of key hormones, and other biochemical markers (eg, 17-B estradiol, LH, FSH, testosterone), lipid profile (Hero, 2005; Shulman, 2008; Wickman, 2001)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">McCune-Albright syndrome: In the pediatric clinical trial (study duration: 12-36 months), the following were monitored (baseline, every 6 months): Rates of growth and bone age advance, levels of indices of bone metabolism (eg, osteocalcin and alkaline phosphatase); and urinary markers of steroid metabolism (eg, hydroxyproline, pyridinoline, etc.), mean ovarian volume, episodes of vaginal bleeding and serum concentrations of estradiol. (Feuillan, 2007)  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187251\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system which binds to the heme group of aromatase, a cytochrome P450 enzyme which catalyzes conversion of androgens to estrogens (specifically, androstenedione to estrone and testosterone to estradiol). This leads to inhibition of the enzyme and a significant reduction in plasma estrogen (estrone, estradiol and estrone sulfate) levels. Letrozole does not appear to affect synthesis of adrenal or thyroid hormones, aldosterone, or androgens.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187267\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Rapid and well absorbed; not affected by food</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: ~1.9 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding, plasma: Weak</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic via CYP3A4 and 2A6 to an inactive carbinol metabolite</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Terminal: ~2 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to steady state, plasma: 2 to 6 weeks; steady state serum concentrations are 1.5 to 2 times higher than single-dose values. In girls 3 to 9 years, steady state concentrations were 25% to 67% that of the mean adult values (Feuillan 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~90%; 6% as unchanged drug, 75% as glucuronide carbinol metabolite, 9% as unidentified metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187270\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Femara Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (30): $842.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Letrozole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (30): $543.44</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F187273\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Antif (PE);</li>\n      <li>Aromara (ID);</li>\n      <li>Avomit (HR);</li>\n      <li>Bretra (KR);</li>\n      <li>Eirfem (IE);</li>\n      <li>Elozora (RO);</li>\n      <li>Endofree (BD);</li>\n      <li>Esmara (KR);</li>\n      <li>Etruzyl (UA);</li>\n      <li>Famara (UA);</li>\n      <li>Femaplex (ID);</li>\n      <li>Femar (IS, NO);</li>\n      <li>Femara (AE, AR, AT, AU, BB, BD, BE, BG, BH, BO, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EE, EG, ES, FI, FR, GB, GR, HK, HR, HU, IE, IL, IQ, IR, IT, JO, JP, KR, KW, LB, LT, LU, LV, LY, MT, MX, MY, NL, NO, NZ, OM, PE, PH, PK, PL, PR, PT, PY, QA, RO, RU, SA, SE, SG, SI, SK, SY, TH, TR, TW, UY, VE, VN, YE);</li>\n      <li>Femgard (CO);</li>\n      <li>Femolet (AU);</li>\n      <li>Fera (AU);</li>\n      <li>Fezol (BD);</li>\n      <li>Fu Rui (CN);</li>\n      <li>Gesamef (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Glotraz (LK);</li>\n      <li>Hentrozole (PH);</li>\n      <li>Lenara (KR);</li>\n      <li>Lenor (BD);</li>\n      <li>Lentronat (SG);</li>\n      <li>Lerozol (LK);</li>\n      <li>Letara (AU, NZ);</li>\n      <li>Letero (SG, TH);</li>\n      <li>Letoripe (PH);</li>\n      <li>Letov (LK, TH);</li>\n      <li>Letraz (ID);</li>\n      <li>Letrol (BD);</li>\n      <li>Letronat (MY);</li>\n      <li>Letrostad (PH);</li>\n      <li>Letroz (PH, PY);</li>\n      <li>Letvex (PH);</li>\n      <li>Letzo (IE);</li>\n      <li>Letzol (IN);</li>\n      <li>Lexel (BD);</li>\n      <li>Lezol (PH);</li>\n      <li>Lezra (ID, PH, SG, UA, VN);</li>\n      <li>Likarda (LV);</li>\n      <li>Losiral (EC);</li>\n      <li>Trodis (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Trozet (PH, TH, TW);</li>\n      <li>Zolet (LK);</li>\n      <li>Zolstro (CR, DO, GT, HN, NI, PA, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Feuillan P, Calis K, Hill S, Shawker T, Robey PG, Collins MT. Letrozole treatment of precocious puberty in girls with McCune-Albright syndrome: a pilot study. <i>J Clin Endocrinol Metab</i>. 2007;92:2100-2106.  <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-pediatric-drug-information/abstract-text/17405850/pubmed\" target=\"_blank\" id=\"17405850\">17405850</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goss PE, Ingle JN, Martino S,  et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. <i>N Engl J Med</i>. 2003;349(19):1793-1802.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-pediatric-drug-information/abstract-text/14551341 /pubmed\" target=\"_blank\" id=\"14551341 \">14551341 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hero M, Norjavaara E, Dunkel L. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. <i>J Clin Endocrinol Metab</i>. 2005;90:6396-6402.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-pediatric-drug-information/abstract-text/16189252/pubmed\" target=\"_blank\" id=\"16189252\">16189252</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jin H, Tu D, Zhao N, Shepherd LE, Goss PE. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. <i>J Clin Oncol</i>. 2012;30(7):718-721.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-pediatric-drug-information/abstract-text/22042967 /pubmed\" target=\"_blank\" id=\"22042967 \">22042967 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Karmazin A, Moore WV, Popovic J, Jacobson JD. The effect of letrozole on bone age progression, predicted adult height, and adrenal gland function. <i>J Pediatr Endocrinol Metab</i>.  2005;18:285-293.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-pediatric-drug-information/abstract-text/15813607/pubmed\" target=\"_blank\" id=\"15813607\">15813607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palmert MR, Dunkel L. Clinical practice. Delayed puberty. <i>N Engl J Med</i>. 2012;366(5):443-453.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-pediatric-drug-information/abstract-text/22296078/pubmed\" target=\"_blank\" id=\"22296078\">22296078</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shulman DI, Francis GL, Palmert MR, et al. Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development. <i>Pediatrics</i>. 2008;121(4):e975-983.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-pediatric-drug-information/abstract-text/18381525/pubmed\" target=\"_blank\" id=\"18381525\">18381525</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wickman S, Dunkel L. Inhibition of P450 aromatase enhances gonadotropin secretion in early and midpubertal boys: evidence for a pituitary site of action of endogenous E. <i>J Clin Endocrinol Metab</i>. 2001;86(10):4887-4894. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-pediatric-drug-information/abstract-text/11600558/pubmed\" target=\"_blank\" id=\"11600558\">11600558</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wickman S, Sipil&auml; I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled.  <i>Lancet</i>.  2001;357:1743-1748.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/letrozole-pediatric-drug-information/abstract-text/11403810/pubmed\" target=\"_blank\" id=\"11403810\">11403810</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 94329 Version 75.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F187285\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F187286\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1021526\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1021558\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F187263\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F187248\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F24037031\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104527\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F187281\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1021527\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F187326\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F187324\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F187268\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F187252\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26021958\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F187313\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F187257\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F187271\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1021564\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F187251\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F187267\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F187270\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F187273\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/94329|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=letrozole-drug-information\" class=\"drug drug_general\">Letrozole: Drug information</a></li><li><a href=\"topic.htm?path=letrozole-patient-drug-information\" class=\"drug drug_patient\">Letrozole: Patient drug information</a></li></ul></div></div>","javascript":null}